UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 78 filers reported holding UROGEN PHARMA LTD in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,265,464 | +23.2% | 2,303,031 | -9.0% | 0.29% | +21.1% |
| Q2 2023 | $26,183,637 | -2.9% | 2,529,820 | -13.3% | 0.24% | -13.3% |
| Q1 2023 | $26,971,588 | +4.2% | 2,919,003 | 0.0% | 0.28% | -36.0% |
| Q4 2022 | $25,891,557 | +6.6% | 2,919,003 | 0.0% | 0.44% | -4.8% |
| Q3 2022 | $24,286,000 | +0.5% | 2,919,003 | -1.0% | 0.46% | +4.1% |
| Q2 2022 | $24,156,000 | -6.1% | 2,949,489 | -0.1% | 0.44% | +18.3% |
| Q1 2022 | $25,716,000 | -8.4% | 2,952,489 | 0.0% | 0.37% | -2.6% |
| Q4 2021 | $28,078,000 | -43.5% | 2,952,489 | -0.1% | 0.38% | -47.4% |
| Q3 2021 | $49,698,000 | +10.2% | 2,954,699 | 0.0% | 0.73% | +11.9% |
| Q2 2021 | $45,118,000 | -21.6% | 2,954,699 | 0.0% | 0.65% | -31.2% |
| Q1 2021 | $57,558,000 | +8.1% | 2,954,699 | 0.0% | 0.94% | +1.5% |
| Q4 2020 | $53,244,000 | -6.6% | 2,954,699 | 0.0% | 0.93% | -26.6% |
| Q3 2020 | $56,996,000 | -26.1% | 2,954,699 | 0.0% | 1.27% | -33.0% |
| Q2 2020 | $77,177,000 | +46.4% | 2,954,699 | 0.0% | 1.89% | +31.7% |
| Q1 2020 | $52,712,000 | -46.5% | 2,954,699 | 0.0% | 1.44% | -38.9% |
| Q4 2019 | $98,598,000 | +40.0% | 2,954,699 | 0.0% | 2.35% | +37.4% |
| Q3 2019 | $70,410,000 | -33.7% | 2,954,699 | 0.0% | 1.71% | -40.5% |
| Q2 2019 | $106,192,000 | -2.7% | 2,954,699 | 0.0% | 2.87% | -1.9% |
| Q1 2019 | $109,147,000 | +1.4% | 2,954,699 | +18.2% | 2.93% | -5.8% |
| Q4 2018 | $107,644,000 | -8.8% | 2,499,870 | 0.0% | 3.11% | -2.7% |
| Q3 2018 | $118,069,000 | -5.1% | 2,499,870 | 0.0% | 3.20% | -9.3% |
| Q2 2018 | $124,394,000 | +22.4% | 2,499,870 | +22.2% | 3.53% | +9.5% |
| Q1 2018 | $101,647,000 | +80.9% | 2,045,629 | +35.5% | 3.22% | +48.5% |
| Q4 2017 | $56,187,000 | +213.0% | 1,510,007 | +165.1% | 2.17% | +197.5% |
| Q3 2017 | $17,953,000 | +670.2% | 569,589 | +341.4% | 0.73% | +568.8% |
| Q2 2017 | $2,331,000 | – | 129,055 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |